Johnson & Johnson (Pty) Ltd’s $13.1bn acquisition of Shockwave Medical will greatly expand the medtech’s cardiovascular portfolio. Wells Fargo analyst Larry Biegelsen expects that the deal will also accelerate its top-line growth.
J&J said on 5 April, it would pay $335 a share in cash for Shockwave and expects to fund the deal with cash and debt